-
Something wrong with this record ?
Chiral capillary zone electrophoresis in enantioseparation and analysis of cinacalcet impurities: Use of Quality by Design principles in method development
B. Pasquini, S. Orlandini, M. Villar-Navarro, C. Caprini, M. Del Bubba, M. Douša, A. Giuffrida, R. Gotti, S. Furlanetto,
Language English Country Netherlands
Document type Journal Article
- MeSH
- beta-Cyclodextrins chemistry MeSH
- Cinacalcet chemistry isolation & purification MeSH
- Electrophoresis, Capillary methods MeSH
- gamma-Cyclodextrins chemistry MeSH
- Risk Assessment MeSH
- Hydrogen-Ion Concentration MeSH
- Drug Contamination MeSH
- Monte Carlo Method MeSH
- Probability MeSH
- Solvents MeSH
- Stereoisomerism MeSH
- Publication type
- Journal Article MeSH
A capillary electrophoresis method for the simultaneous determination of the enantiomeric purity and of impurities of the chiral calcimimetic drug cinacalcet hydrochloride has been developed following Quality by Design principles. The scouting phase was aimed to select the separation operative mode and to identify a suitable chiral selector. Among the tested cyclodextrins, (2-carboxyethyl)-β-cyclodextrin and (2-hydroxypropyl)-γ-cyclodextrin (HPγCyD) showed good chiral resolving capabilities. The selected separation system was solvent-modified capillary zone electrophoresis with the addition of HPγCyD and methanol. Voltage, buffer pH, methanol concentration and HPγCyD concentration were investigated as critical method parameters by a multivariate strategy. Critical method attributes were represented by enantioresolution and analysis time. A Box-Behnken Design allowed the contour plots to be drawn and quadratic and interaction effects to be highlighted. The Method Operable Design Region (MODR) was identified by applying Monte-Carlo simulations and corresponded to the multidimensional zone where both the critical method attributes fulfilled the requirements with a desired probability π≥90%. The working conditions, with the MODR limits, corresponded to the following: capillary length, 48.5cm; temperature, 18°C; voltage, 26kV (26-27kV); background electrolyte, 150mM phosphate buffer pH 2.70 (2.60-2.80), 3.1mM (3.0-3.5mM) HPγCyD; 2.00% (0.00-8.40%) v/v methanol. Robustness testing was carried out by a Plackett-Burman matrix and finally a method control strategy was defined. The complete separation of the analytes was obtained in about 10min. The method was validated following the International Council for Harmonisation guidelines and was applied for the analysis of a real sample of cinacalcet hydrochloride tablets.
Department of Analytical Chemistry Faculty of Chemistry University of Seville 41012 Seville Spain
Department of Chemical Sciences University of Catania Viale A Doria 6 95125 Catania Italy
Department of Pharmacy and Biotechnology University of Bologna Via Belmeloro 6 40126 Bologna Italy
Zentiva K S Praha a Sanofi Company U Kabelovny 130 102 37 Praha 10 Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033009
- 003
- CZ-PrNML
- 005
- 20181008122205.0
- 007
- ta
- 008
- 181008s2018 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.chroma.2018.07.021 $2 doi
- 035 __
- $a (PubMed)30005942
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Pasquini, Benedetta $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy.
- 245 10
- $a Chiral capillary zone electrophoresis in enantioseparation and analysis of cinacalcet impurities: Use of Quality by Design principles in method development / $c B. Pasquini, S. Orlandini, M. Villar-Navarro, C. Caprini, M. Del Bubba, M. Douša, A. Giuffrida, R. Gotti, S. Furlanetto,
- 520 9_
- $a A capillary electrophoresis method for the simultaneous determination of the enantiomeric purity and of impurities of the chiral calcimimetic drug cinacalcet hydrochloride has been developed following Quality by Design principles. The scouting phase was aimed to select the separation operative mode and to identify a suitable chiral selector. Among the tested cyclodextrins, (2-carboxyethyl)-β-cyclodextrin and (2-hydroxypropyl)-γ-cyclodextrin (HPγCyD) showed good chiral resolving capabilities. The selected separation system was solvent-modified capillary zone electrophoresis with the addition of HPγCyD and methanol. Voltage, buffer pH, methanol concentration and HPγCyD concentration were investigated as critical method parameters by a multivariate strategy. Critical method attributes were represented by enantioresolution and analysis time. A Box-Behnken Design allowed the contour plots to be drawn and quadratic and interaction effects to be highlighted. The Method Operable Design Region (MODR) was identified by applying Monte-Carlo simulations and corresponded to the multidimensional zone where both the critical method attributes fulfilled the requirements with a desired probability π≥90%. The working conditions, with the MODR limits, corresponded to the following: capillary length, 48.5cm; temperature, 18°C; voltage, 26kV (26-27kV); background electrolyte, 150mM phosphate buffer pH 2.70 (2.60-2.80), 3.1mM (3.0-3.5mM) HPγCyD; 2.00% (0.00-8.40%) v/v methanol. Robustness testing was carried out by a Plackett-Burman matrix and finally a method control strategy was defined. The complete separation of the analytes was obtained in about 10min. The method was validated following the International Council for Harmonisation guidelines and was applied for the analysis of a real sample of cinacalcet hydrochloride tablets.
- 650 _2
- $a cinakalcet $x chemie $x izolace a purifikace $7 D000069449
- 650 _2
- $a kontaminace léku $7 D004340
- 650 _2
- $a elektroforéza kapilární $x metody $7 D019075
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a metoda Monte Carlo $7 D009010
- 650 _2
- $a pravděpodobnost $7 D011336
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rozpouštědla $7 D012997
- 650 _2
- $a stereoizomerie $7 D013237
- 650 _2
- $a beta-cyklodextriny $x chemie $7 D047392
- 650 _2
- $a gama-cyklodextriny $x chemie $7 D047408
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Orlandini, Serena $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy. Electronic address: serena.orlandini@unifi.it.
- 700 1_
- $a Villar-Navarro, Mercedes $u Department of Analytical Chemistry, Faculty of Chemistry, University of Seville, 41012, Seville, Spain.
- 700 1_
- $a Caprini, Claudia $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy.
- 700 1_
- $a Del Bubba, Massimo $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy.
- 700 1_
- $a Douša, Michal $u Zentiva, K.S. Praha, a Sanofi Company, U Kabelovny 130, 102 37, Praha 10, Czech Republic.
- 700 1_
- $a Giuffrida, Alessandro $u Department of Chemical Sciences, University of Catania, Viale A. Doria 6, 95125, Catania, Italy.
- 700 1_
- $a Gotti, Roberto $u Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy.
- 700 1_
- $a Furlanetto, Sandra $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019, Sesto Fiorentino, Florence, Italy. Electronic address: sandra.furlanetto@unifi.it.
- 773 0_
- $w MED00004962 $t Journal of chromatography. A $x 1873-3778 $g Roč. 1568, č. - (2018), s. 205-213
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30005942 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181008122651 $b ABA008
- 999 __
- $a ok $b bmc $g 1339342 $s 1030003
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 1568 $c - $d 205-213 $e 20180705 $i 1873-3778 $m Journal of chromatography. A, Including electrophoresis and other separation methods $n J Chromatogr A $x MED00004962
- LZP __
- $a Pubmed-20181008